Evidence map›Paper›PMID 39009599›Full record

ArticleNature communications2024

Engineered reversible inhibition of SpyCatcher reactivity enables rapid generation of bispecific antibodies.

Christian Hentrich, Mateusz Putyrski, Hanh Hanuschka, Waldemar Preis, Sarah-Jane Kellmann, Melissa Wich, Manuel Cavada, Sarah Hanselka, Victor S Lelyveld, Francisco Ylera

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Christian Hentrich *Bio-Rad AbD Serotec GmbH, Anna-Sigmund-Str. 5, 82061, Neuried, Germany.
Mateusz Putyrski *Bio-Rad AbD Serotec GmbH, Anna-Sigmund-Str. 5, 82061, Neuried, Germany.
Hanh HanuschkaBio-Rad AbD Serotec GmbH, Anna-Sigmund-Str. 5, 82061, Neuried, Germany.
Waldemar PreisBio-Rad AbD Serotec GmbH, Anna-Sigmund-Str. 5, 82061, Neuried, Germany.
Sarah-Jane KellmannBio-Rad AbD Serotec GmbH, Anna-Sigmund-Str. 5, 82061, Neuried, Germany.
Melissa WichBio-Rad AbD Serotec GmbH, Anna-Sigmund-Str. 5, 82061, Neuried, Germany.
Manuel CavadaBio-Rad AbD Serotec GmbH, Anna-Sigmund-Str. 5, 82061, Neuried, Germany.
Sarah HanselkaBio-Rad AbD Serotec GmbH, Anna-Sigmund-Str. 5, 82061, Neuried, Germany.
Victor S LelyveldDepartment of Molecular Biology, Massachusetts General Hospital, Boston, MA, USA.
Francisco YleraBio-Rad AbD Serotec GmbH, Anna-Sigmund-Str. 5, 82061, Neuried, Germany. francisco_ylera@bio-rad.com.ORCID 0000-0002-3230-4151

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The precise regulation of protein function is essential in biological systems and a key goal in chemical biology and protein engineering. Here, we describe a straightforward method to engineer functional control into the isopeptide bond-forming SpyTag/SpyCatcher protein ligation system. First, we perform a cysteine scan of the structured region of SpyCatcher. Except for two known reactive and catalytic residues, none of these mutations abolish reactivity. In a second screening step, we modify the cysteines with disulfide bond-forming small molecules. Here we identify 8 positions at which modifications strongly inhibit reactivity. This inhibition can be reversed by reducing agents. We call such a reversibly inhibitable SpyCatcher "SpyLock". Using "BiLockCatcher", a genetic fusion of wild-type SpyCatcher and SpyLock, and SpyTagged antibody fragments, we generate bispecific antibodies in a single, scalable format, facilitating the screening of a large number of antibody combinations. We demonstrate this approach by screening anti-PD-1/anti-PD-L1 bispecific antibodies using a cellular reporter assay.

Indexed as

Antibodies, BispecificCysteineProtein EngineeringAnimalsB7-H1 AntigenDisulfidesHEK293 CellsHumansProgrammed Cell Death 1 ReceptorAntibodies, BispecificB7-H1 AntigenCD274 protein, humanCysteineDisulfidesPDCD1 protein, humanProgrammed Cell Death 1 Receptor

Identifiers

PMID39009599
PMCPMC11251281

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.